Capturing cell 'fingerprints' to advance cancer screening

July 9, 2009

( -- Researchers at Northeastern University have developed an early-stage, highly accurate cancer screening technology that determines -- in seconds -- whether a cell is cancerous, precancerous or normal.

The breakthrough technology, for which there is a patent pending, automatically captures a “fingerprint” of the cell’s biochemical composition, which is subsequently analyzed by a computer for abnormalities.

The new method, which currently can screen for oral, cervical and head-and-neck cancers, is faster, more accurate, and enables earlier detection than current screening methods. Those methods rely on the visual detection, under a microscope, of a few abnormally shaped cells among thousands.

Referred to as Spectral Cytopathology (SCP), the technology was pioneered by professor of chemistry and chemical biology Max Diem, head of Northeastern’s Laboratory for Spectral Diagnosis; chemistry and chemical biology research scientists Melissa Romeo, Ben Bird and Miloš Miljkovic; and several Northeastern graduate and undergraduate students.

“We are looking beyond traditional methods by focusing on detecting cellular changes that happen in the earlier stages of cancer, which will have a tremendous impact on patients,” said Diem.

“Cytologists [scientists who study the structure and function of cells] have the most difficulty identifying pre-cancers in the earliest stages,” said Romeo. “Our technology offers the ability to detect abnormal changes in cells even before (structural) changes become apparent.”

Earlier detection combined with greater accuracy—SCP has a greater-than 95 percent accuracy rate compared to 65 to 70 percent for current screening methods—would make a significant difference in patient survival rates.

The high death rate associated with oral cancer, for example, results from late- stage diagnoses, often after the cancer has metastasized. When discovered early, however, oral cancers have an 80 to 90 percent survival rate.

The technology behind SCP works by capturing a cell’s biochemical composition. After a cell sample is obtained through a minimally invasive exfoliation procedure, the cells are probed with infrared light, which interacts with the cell’s molecular components and produces a “fingerprint” of each cell’s biochemical composition. The data is analyzed by a computer, which reports if the cells are normal, cancerous or precancerous.

Traditional screening methods require cytologists to detect abnormalities by examining cells under a to discover very subtle structural changes in just a few among as many as 10,000.

The new technology, which Diem estimates is no more than five years away from bringing into application, would relieve a testing logjam at existing cytology laboratories. There is a shortage of cytologists able to conduct the tests, he said, limiting the number of screenings that can be performed.

SCP “could be applied to several other forms of cancer and result in more early diagnoses, potentially improving the survival rate of patients with ,” added Diem. “Our ultimate goal is to have this application in doctors’ and dentists’ offices so that patients can be routinely screened.”

Provided by Northeastern University (news : web)

Related Stories

Recommended for you

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.